Edward C. English - Nov 9, 2022 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Principal Accounting Officer
Signature
/c/ Edward C. English
Stock symbol
XLO
Transactions as of
Nov 9, 2022
Transactions value $
$0
Form type
3
Date filed
11/16/2022, 03:16 PM
Next filing
Jan 4, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding XLO Common Stock 6K Nov 9, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XLO Stock Option (right to buy) Nov 9, 2022 Common Stock 16.4K $5.89 Direct F1
holding XLO Stock Option (right to buy) Nov 9, 2022 Common Stock 6.89K $5.89 Direct F2
holding XLO Stock Option (right to buy) Nov 9, 2022 Common Stock 20.8K $10.07 Direct F3
holding XLO Stock Option (right to buy) Nov 9, 2022 Common Stock 9.05K $5.51 Direct F4
holding XLO Stock Option (right to buy) Nov 9, 2022 Common Stock 20.2K $12.66 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 8, 2021. On March 1, 2021, 1/48th of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the 1st day of each month thereafter through February 1, 2025.
F2 The option was granted on March 11, 2021. On April 1, 2021, 1/48th of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the 1st day of each month thereafter through March 1, 2025.
F3 The option was granted on June 17, 2021. On July 1, 2021, 1/48th of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the 1st day of each month thereafter through June 1, 2025.
F4 The option was granted on July 23, 2020. On September 30, 2020, 25% of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the last day of each month thereafter through September 30, 2023.
F5 The option was granted on February 22, 2022. On March 1, 2022, 1/48th of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the 1st day of each month thereafter through February 1, 2026.